Technical Analysis for RVX - Resverlogix Corp.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Volume Surge | Other | 0.00% | |
Narrow Range Bar | Range Contraction | -8.33% | |
Narrow Range Bar | Range Contraction | -8.33% | |
Narrow Range Bar | Range Contraction | -8.33% | |
Narrow Range Bar | Range Contraction | -8.33% | |
20 DMA Resistance | Bearish | -8.33% | |
200 DMA Resistance | Bearish | -8.33% | |
50 DMA Resistance | Bearish | -8.33% | |
MACD Bearish Centerline Cross | Bearish | -8.33% | |
MACD Bearish Signal Line Cross | Bearish | -8.33% |
Alert | Time |
---|---|
Down 1 ATR | about 6 hours ago |
Fell Below Previous Day's Low | about 6 hours ago |
Down 5% | about 6 hours ago |
Down 3% | about 6 hours ago |
Down 2% | about 6 hours ago |
Get a Trading Sidekick!
- Earnings date: 2024-11-07
Resverlogix Corp. Description
Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinic Beta Biotechnology Disease RTT Medical Specialties Diseases IPO Clinical Trial Diabetes Alzheimer's Disease Chronic Condition Chronic Kidney Diabetes Mellitus Kidney Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.095 |
52 Week Low | 0.04 |
Average Volume | 69,917 |
200-Day Moving Average | 0.061 |
50-Day Moving Average | 0.062 |
20-Day Moving Average | 0.063 |
10-Day Moving Average | 0.062 |
Average True Range | 0.004 |
RSI (14) | 40.12 |
ADX | 9.64 |
+DI | 35.253 |
-DI | 41.710 |
Chandelier Exit (Long, 3 ATRs) | 0.058 |
Chandelier Exit (Short, 3 ATRs) | 0.067 |
Upper Bollinger Bands | 0.072 |
Lower Bollinger Band | 0.055 |
Percent B (%b) | 0.01 |
BandWidth | 26.856 |
MACD Line | -0.001 |
MACD Signal Line | 0.000 |
MACD Histogram | -0.0009 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.063 | ||||
Resistance 3 (R3) | 0.063 | 0.062 | 0.061 | ||
Resistance 2 (R2) | 0.062 | 0.060 | 0.061 | 0.061 | |
Resistance 1 (R1) | 0.058 | 0.059 | 0.058 | 0.058 | 0.060 |
Pivot Point | 0.057 | 0.057 | 0.056 | 0.056 | 0.057 |
Support 1 (S1) | 0.053 | 0.055 | 0.053 | 0.053 | 0.050 |
Support 2 (S2) | 0.052 | 0.054 | 0.051 | 0.049 | |
Support 3 (S3) | 0.048 | 0.052 | 0.049 | ||
Support 4 (S4) | 0.048 |